Bromocriptine
Active ingredient: Bromocriptine Mesylate
In short: Bromocriptine mesylate capsules are indicated for the treatment of hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility or hypogonadism in adults. Limitations of Use Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartu
What is Bromocriptine used for?
Bromocriptine mesylate capsules are indicated for the treatment of hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility or hypogonadism in adults.
Limitations of Use
Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions .
Bromocriptine mesylate capsules are indicated for the treatment of prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older.
Bromocriptine mesylate capsules are indicated for the treatment of acromegaly in adults.
Bromocriptine mesylate capsules are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease or postencephalitic parkinsonism in adults.
Bromocriptine dosage
Before initiating bromocriptine mesylate evaluate for valvular heart disease, including with an echocardiogram. If valvular disease is detected, do not administer bromocriptine mesylate .
Take bromocriptine mesylate orally with food because a high percentage of patients vomited after they received bromocriptine mesylate under fasting conditions.
The recommended starting dosage of bromocriptine mesylate in adults with hyperprolactinemia-associated dysfunction is 1.25 mg (one-half of a tablet) to 2.5 mg once daily. Increase the bromocriptine mesylate dosage up to 2.5 mg once daily every two to seven days as tolerated until an optimal therapeutic response is achieved within a recommended dosage of 2.5 mg to 15 mg once daily.
The recommended starting dosage of bromocriptine mesylate in adult and pediatric patients 11 years of age and older with prolactin-secreting adenomas is 1.25 mg (one-half of a tablet) to 2.5 mg once daily. Increase the bromocriptine mesylate dosage as tolerated until an optimal therapeutic response is achieved within a recommended dosage of 2.5 mg to 10 mg once daily.
In cases where adenectomy is elected for prolactin-secreting adenomas, a course of bromocriptine mesylate therapy may be used to reduce the tumor mass prior to surgery.
The recommended starting dosage of bromocriptine mesylate in adults for acromegaly is 1.25 mg (one-half of a tablet) to 2.5 mg once at bedtime for 3 days. Increase the dosage 1.25 mg to 2.5 mg once daily every 3 days to 7 days, as tolerated, until an optimal therapeutic response is achieved. Reevaluate patients monthly and modify the dosage based on growth hormone levels and clinical response. For adults with acromegaly, the usual optimal therapeutic dosage range varies from 20 mg to 30 mg once at bedtime in most patients, and the maximum recommended dosage is 100 mg/daily.
After a brief trial with bromocriptine mesylate therapy in adults with acromegaly, if there is no significant reduction in growth hormone levels and no changes in the clinical features of acromegaly consider increasing the dosage or discontinuing bromocriptine mesylate.
For patients with acromegaly treated with pituitary irradiation, withdraw bromocriptine mesylate (e.g., for four to eight weeks) on a yearly basis to assess the clinical effects of radiation on the disease process as well as the effects of bromocriptine mesylate therapy. Consider restarting bromocriptine mesylate if signs or symptoms of acromegaly or increases in growth hormone occur.
The recommended starting dosage of bromocriptine mesylate in adults with idiopathic Parkinson's disease or postencephalitic parkinsonism is 1.25 mg (one-half of a tablet) twice daily. …
How to take Bromocriptine — instructions & advice from the label
Fibrotic Conditions
There is a risk of cardiac valvulopathy, and pericardial, pleural, pulmonary, and retroperitoneal fibrosis with bromocriptine mesylate treatment Advise patients to notify their healthcare provider if they develop shortness of breath, chest pain, persistent cough, difficulty with breathing when lying down, or swelling in their extremities .
Hypotension/Hypotension
Warn patients about the risk of hypotension and orthostatic hypotension and instruct patients to rise slowly from a supine or sitting position. Advise patients to notify their healthcare provider if they develop dizziness or lightheadedness .
Impulse Control Disorders and Compulsive Behaviors
Patients and their caregivers should be alerted to the possibility that patients may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges, and other intense urges and the inability to control these urges while taking bromocriptine mesylate. Advise patients and their caregivers to inform their health care provider if they develop new or increased uncontrolled spending, gambling urges, sexual urges, or other urges while being treated with bromocriptine mesylate . …
Warnings & precautions
Do not take this medicine if: Bromocriptine mesylate capsules are contraindicated in patients with:
History of cardiac valvular disorders or a history of pericardial fibrosis .
History of pleural, pulmonary, or retroperitoneal fibrotic disorders .
Uncontrolled hypertension .
Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate capsules or sensitivity to other ergot alkaloids.
Before initiating bromocriptine mesylate, perform a cardiovascular evaluation, including with an echocardiogram, to evaluate for valvular disease. Bromocriptine mesylate is contraindicated in the presence of valvular disease or pericardial fibrosis. bromocriptine mesylate is not recommended in patients treated with other drugs associated with valvulopathy. Following bromocriptine mesylate treatment initiation, monitor for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated with new onset edema, cardiac murmur, dyspnea, or heart failure. During bromocriptine mesylate treatment, monitor for chest pain and signs and symptoms of heart failure and if heart failure occurs, valvular fibrosis and pericarditis should be excluded. Consider clinical and diagnostic monitoring such as erythrocyte sedimentation rate, serum creatinine measurements, chest-x-ray, and other investigations and cardiac imaging at baseline and as necessary while patients are treated with during bromocriptine mesylate treatment. Discontinue bromocriptine mesylate capsules if the patient has a new diagnosis of valvular regurgitation, valvular restriction, valve leaflet thickening, or pericarditis.
Cases of cardiac valvulopathy have occurred in bromocriptine mesylate-treated patients. …
Bromocriptine side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Cardiac Valvulopathy and Pericardial Fibrosis
Pleural, Pulmonary, and Retroperitoneal Fibrosis
Hypotension/Orthostatic Hypotension
Risks with Use of bromocriptine mesylate for Postpartum Lactation Inhibition or Suppression
Impulse Control Disorders and Compulsive Behaviors
Falling Asleep During Activities of Daily Living
Visual Impairment in Patients with Prolactin-secreting Adenomas
Exacerbation of Psychosis in Patients with Severe Psychotic Disorders
Risks in Patients with Hereditary Problems of Galactose Intolerance, Severe Lactase Deficiency, or Glucose-Galactose Malabsorption
Additional Clinically Significant Adverse Reactions and Risks in Patients with Acromegaly
Additional Clinically Significant Adverse Reactions and Risks in Patients with Idiopathic Parkinson's Disease or Postencephalitic Parkinsonism
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Studies of Patients with Hyperprolactinemia-Associated Dysfunctions and Prolactin-secreting Adenomas
Bromocriptine mesylate capsules therapy was discontinued in approximately 5% of patients with hyperprolactinemia associated dysfunctions. …
Drug interactions
Alcohol
Alcohol may potentiate bromocriptine mesylate -associated adverse reactions.
Dopamine Antagonists
The concomitant use of bromocriptine mesylate with dopamine antagonists resulted in a decreased efficacy of bromocriptine mesylate.
Strong and Moderate CYP3A4 Inhibitors
Avoid concomitant use of bromocriptine mesylate with strong CYP3A4 inhibitors. Follow the recommended bromocriptine mesylate dosage modifications during concomitant use with moderate CYP3A4 inhibitors .
Bromocriptine is a substrate of CYP3A4 . Concomitant use with strong and moderate CYP3A4 inhibitors increases bromocriptine exposure , which may increase the risk of bromocriptine mesylate-associated adverse reactions.
Ergot Alkaloids
Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended. If use is unavoidable, dosage reduction may be necessary in those cases where high dosages of bromocriptine mesylate are being used (such as patients with Parkinson's disease).
About this medicine
Bromocriptine mesylate is an ergot derivative with potent dopamine receptor agonist activity. Bromocriptine mesylate is chemically designated as Ergotaman-3΄, 6΄, 18-trione, 2-bromo-12΄-hydroxy-2΄-(1-methylethyl)-5΄-(2-methylpropyl)-, (5΄α)-mono-methanesulfonate (salt).
The structural formula is:
C32H40BrN5O5.CH4SO3 | Mol. wt. 750.70
Bromocriptine mesylate, USP is white or slightly colored, fine crystalline powder and odorless or having a weak, characteristic odor.
Each bromocriptine mesylate capsule USP, 5 mg intended for oral administration contains bromocriptine mesylate equivalent to 5 mg of bromocriptine. In addition, each capsule contains the following inactive ingredients: carrageenan, colloidal silicon dioxide, hypromellose, iron oxide red, lactose monohydrate, magnesium stearate, maleic acid, potassium hydroxide and titanium dioxide. Each capsule is printed with black pharmaceutical ink and has following inactive ingredients: black iron oxide, potassium hydroxide, propylene glycol, purified water, shellac and strong ammonia solution. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d69003ee-0b6f-47a9-834e-ba59c02f566c. Read the full official label on DailyMed.